Bailard Inc. Makes New Investment in argenex SE $ARGX

Bailard Inc. purchased a new stake in argenex SE (NASDAQ:ARGX) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 1,001 shares of the company’s stock, valued at approximately $738,000.

Several other hedge funds also recently made changes to their positions in ARGX. GAMMA Investing LLC lifted its stake in argenex by 6.8% during the third quarter. GAMMA Investing LLC now owns 251 shares of the company’s stock valued at $185,000 after purchasing an additional 16 shares during the last quarter. Cromwell Holdings LLC increased its holdings in shares of argenex by 10.0% in the third quarter. Cromwell Holdings LLC now owns 187 shares of the company’s stock valued at $138,000 after buying an additional 17 shares in the last quarter. Main Management ETF Advisors LLC lifted its position in shares of argenex by 1.7% during the 2nd quarter. Main Management ETF Advisors LLC now owns 1,466 shares of the company’s stock valued at $808,000 after acquiring an additional 24 shares during the last quarter. Wilmington Savings Fund Society FSB boosted its stake in shares of argenex by 1.1% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 2,126 shares of the company’s stock worth $1,568,000 after acquiring an additional 24 shares in the last quarter. Finally, IFP Advisors Inc grew its holdings in shares of argenex by 4.2% in the 2nd quarter. IFP Advisors Inc now owns 666 shares of the company’s stock worth $367,000 after acquiring an additional 27 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Stock Performance

Shares of ARGX opened at $814.74 on Friday. The company has a market capitalization of $50.42 billion, a PE ratio of 34.98, a PEG ratio of 0.53 and a beta of 0.38. The company’s 50 day moving average price is $859.47 and its 200 day moving average price is $771.27. argenex SE has a 52 week low of $510.05 and a 52 week high of $934.62.

argenex (NASDAQ:ARGX) last released its earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The company had revenue of $1.12 billion during the quarter, compared to the consensus estimate of $1.07 billion. On average, equities analysts forecast that argenex SE will post 3.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ARGX has been the subject of several analyst reports. Evercore ISI upped their target price on argenex from $775.00 to $910.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Wells Fargo & Company upped their price objective on shares of argenex from $1,264.00 to $1,317.00 and gave the company an “overweight” rating in a research note on Tuesday. Citigroup dropped their target price on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. HC Wainwright upped their price target on shares of argenex from $774.00 to $915.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Finally, Wall Street Zen lowered shares of argenex from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, argenex currently has an average rating of “Moderate Buy” and an average target price of $986.78.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.